Get App

Lupin's Vizag unit gets no observations from USFDA

“We are pleased with the successful completion of the inspection at our Vizag facility. This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all,” said Nilesh Gupta, managing director of Lupin.
  • Updated On Mar 11, 2023 at 05:38 AM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
Drug maker Lupin on Friday said a pre-approval and good manufacturing practices (GMP) inspection conducted by USFDA of its active pharmaceutical ingredient (API) manufacturing facility in Visakhapatnam concluded without any observations.

The inspection was conducted from March 6 - 10, 2023

“We are pleased with the successful completion of the inspection at our Vizag facility,” said Nilesh Gupta, managing director of Lupin.

“This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all,” Gupta added.

Advt
  • Published On Mar 11, 2023 at 05:38 AM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App